View in EDS

Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).

Saved in:
Bibliographic Details
Title: Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
Authors: Issa GC; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Aldoss I; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA., Thirman MJ; Biological Sciences Division, The University of Chicago Medicine, Chicago, IL., DiPersio J; John T. Milliken Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO., Arellano M; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA., Blachly JS; Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH., Mannis GN; Division of Hematology, Stanford University School of Medicine, Stanford, CA., Perl A; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA., Dickens DS; University of Iowa Stead Family Children's Hospital, Iowa City, IA., McMahon CM; UCHealth Blood Disorders and Cell Therapies Center, University of Colorado School of Medicine, Aurora, CO., Traer E; Knight Cancer Institute, Oregon Health & Science University, Portland, OR., Zwaan CM; Princess Máxima Center for Pediatric Oncology, Utrecht, and Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands., Grove CS; Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia., Stone R; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA., Shami PJ; University of Utah Huntsman Cancer Institute, Salt Lake City, UT., Mantzaris I; Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY., Greenwood M; Department of Haematology, Royal North Shore Hospital, The University of Sydney, Sydney, New South Wales, Australia., Shukla N; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY., Cuglievan B; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX., Kovacsovics T; City of Hope Phoenix, Goodyear, AZ., Gu Y; Syndax Pharmaceuticals, Inc, Waltham, MA., Bagley RG; Syndax Pharmaceuticals, Inc, Waltham, MA., Madigan K; Syndax Pharmaceuticals, Inc, Waltham, MA., Chudnovsky Y; Syndax Pharmaceuticals, Inc, Waltham, MA., Nguyen HV; Syndax Pharmaceuticals, Inc, Waltham, MA., McNeer N; Syndax Pharmaceuticals, Inc, Waltham, MA., Stein EM; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.
Source: Journal of clinical oncology : official journal of the American Society of Clinical Oncology [J Clin Oncol] 2025 Jan; Vol. 43 (1), pp. 75-84. Date of Electronic Publication: 2024 Aug 09.
Publication Type: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Society of Clinical Oncology Country of Publication: United States NLM ID: 8309333 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1527-7755 (Electronic) Linking ISSN: 0732183X NLM ISO Abbreviation: J Clin Oncol Subsets: MEDLINE
Database: MEDLINE Ultimate
FullText Text:
  Availability: 0
Header DbId: mdl
DbLabel: MEDLINE Ultimate
An: 39121437
AccessLevel: 2
PubType: Academic Journal
PubTypeId: academicJournal
PreciseRelevancyScore: 0
IllustrationInfo
Items – Name: Title
  Label: Title
  Group: Ti
  Data: Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
– Name: Author
  Label: Authors
  Group: Au
  Data: <searchLink fieldCode="AU" term="%22Issa+GC%22">Issa GC</searchLink>; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Aldoss+I%22">Aldoss I</searchLink>; Department of Hematology & Hematopoietic Cell Transplantation, City of Hope National Medical Center, Duarte, CA.<br /><searchLink fieldCode="AU" term="%22Thirman+MJ%22">Thirman MJ</searchLink>; Biological Sciences Division, The University of Chicago Medicine, Chicago, IL.<br /><searchLink fieldCode="AU" term="%22DiPersio+J%22">DiPersio J</searchLink>; John T. Milliken Department of Medicine, Division of Oncology, Washington University School of Medicine, St Louis, MO.<br /><searchLink fieldCode="AU" term="%22Arellano+M%22">Arellano M</searchLink>; Winship Cancer Institute, Emory University School of Medicine, Atlanta, GA.<br /><searchLink fieldCode="AU" term="%22Blachly+JS%22">Blachly JS</searchLink>; Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, The Ohio State University, Columbus, OH.<br /><searchLink fieldCode="AU" term="%22Mannis+GN%22">Mannis GN</searchLink>; Division of Hematology, Stanford University School of Medicine, Stanford, CA.<br /><searchLink fieldCode="AU" term="%22Perl+A%22">Perl A</searchLink>; Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA.<br /><searchLink fieldCode="AU" term="%22Dickens+DS%22">Dickens DS</searchLink>; University of Iowa Stead Family Children's Hospital, Iowa City, IA.<br /><searchLink fieldCode="AU" term="%22McMahon+CM%22">McMahon CM</searchLink>; UCHealth Blood Disorders and Cell Therapies Center, University of Colorado School of Medicine, Aurora, CO.<br /><searchLink fieldCode="AU" term="%22Traer+E%22">Traer E</searchLink>; Knight Cancer Institute, Oregon Health & Science University, Portland, OR.<br /><searchLink fieldCode="AU" term="%22Zwaan+CM%22">Zwaan CM</searchLink>; Princess Máxima Center for Pediatric Oncology, Utrecht, and Erasmus MC-Sophia Children's Hospital, Rotterdam, the Netherlands.<br /><searchLink fieldCode="AU" term="%22Grove+CS%22">Grove CS</searchLink>; Department of Haematology, Sir Charles Gairdner Hospital, Nedlands, Australia.<br /><searchLink fieldCode="AU" term="%22Stone+R%22">Stone R</searchLink>; Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA.<br /><searchLink fieldCode="AU" term="%22Shami+PJ%22">Shami PJ</searchLink>; University of Utah Huntsman Cancer Institute, Salt Lake City, UT.<br /><searchLink fieldCode="AU" term="%22Mantzaris+I%22">Mantzaris I</searchLink>; Department of Oncology, Montefiore Einstein Comprehensive Cancer Center, Bronx, NY.<br /><searchLink fieldCode="AU" term="%22Greenwood+M%22">Greenwood M</searchLink>; Department of Haematology, Royal North Shore Hospital, The University of Sydney, Sydney, New South Wales, Australia.<br /><searchLink fieldCode="AU" term="%22Shukla+N%22">Shukla N</searchLink>; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.<br /><searchLink fieldCode="AU" term="%22Cuglievan+B%22">Cuglievan B</searchLink>; Department of Leukemia, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX.<br /><searchLink fieldCode="AU" term="%22Kovacsovics+T%22">Kovacsovics T</searchLink>; City of Hope Phoenix, Goodyear, AZ.<br /><searchLink fieldCode="AU" term="%22Gu+Y%22">Gu Y</searchLink>; Syndax Pharmaceuticals, Inc, Waltham, MA.<br /><searchLink fieldCode="AU" term="%22Bagley+RG%22">Bagley RG</searchLink>; Syndax Pharmaceuticals, Inc, Waltham, MA.<br /><searchLink fieldCode="AU" term="%22Madigan+K%22">Madigan K</searchLink>; Syndax Pharmaceuticals, Inc, Waltham, MA.<br /><searchLink fieldCode="AU" term="%22Chudnovsky+Y%22">Chudnovsky Y</searchLink>; Syndax Pharmaceuticals, Inc, Waltham, MA.<br /><searchLink fieldCode="AU" term="%22Nguyen+HV%22">Nguyen HV</searchLink>; Syndax Pharmaceuticals, Inc, Waltham, MA.<br /><searchLink fieldCode="AU" term="%22McNeer+N%22">McNeer N</searchLink>; Syndax Pharmaceuticals, Inc, Waltham, MA.<br /><searchLink fieldCode="AU" term="%22Stein+EM%22">Stein EM</searchLink>; Department of Pediatrics, Memorial Sloan Kettering Cancer Center, New York, NY.
– Name: TitleSource
  Label: Source
  Group: Src
  Data: <searchLink fieldCode="JN" term="%228309333%22">Journal of clinical oncology : official journal of the American Society of Clinical Oncology</searchLink> [J Clin Oncol] 2025 Jan; Vol. 43 (1), pp. 75-84. <i>Date of Electronic Publication: </i>2024 Aug 09.
– Name: TypePub
  Label: Publication Type
  Group: TypPub
  Data: Journal Article; Clinical Trial, Phase I; Clinical Trial, Phase II; Multicenter Study; Research Support, Non-U.S. Gov't; Research Support, N.I.H., Extramural
– Name: TitleSource
  Label: Journal Info
  Group: Src
  Data: <i>Publisher: </i><searchLink fieldCode="PB" term="%22American+Society+of+Clinical+Oncology%22">American Society of Clinical Oncology </searchLink><i>Country of Publication: </i>United States <i>NLM ID: </i>8309333 <i>Publication Model: </i>Print-Electronic <i>Cited Medium: </i>Internet <i>ISSN: </i>1527-7755 (Electronic) <i>Linking ISSN: </i><searchLink fieldCode="IS" term="%220732183X%22">0732183X </searchLink><i>NLM ISO Abbreviation: </i>J Clin Oncol <i>Subsets: </i>MEDLINE
PLink https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&db=mdl&AN=39121437
RecordInfo BibRecord:
  BibEntity:
    Identifiers:
      – Type: doi
        Value: 10.1200/JCO.24.00826
    Languages:
      – Code: eng
        Text: English
    PhysicalDescription:
      Pagination:
        StartPage: 75
    Titles:
      – TitleFull: Menin Inhibition With Revumenib for KMT2A-Rearranged Relapsed or Refractory Acute Leukemia (AUGMENT-101).
        Type: main
  BibRelationships:
    HasContributorRelationships:
      – PersonEntity:
          Name:
            NameFull: Issa GC
      – PersonEntity:
          Name:
            NameFull: Aldoss I
      – PersonEntity:
          Name:
            NameFull: Thirman MJ
      – PersonEntity:
          Name:
            NameFull: DiPersio J
      – PersonEntity:
          Name:
            NameFull: Arellano M
      – PersonEntity:
          Name:
            NameFull: Blachly JS
      – PersonEntity:
          Name:
            NameFull: Mannis GN
      – PersonEntity:
          Name:
            NameFull: Perl A
      – PersonEntity:
          Name:
            NameFull: Dickens DS
      – PersonEntity:
          Name:
            NameFull: McMahon CM
      – PersonEntity:
          Name:
            NameFull: Traer E
      – PersonEntity:
          Name:
            NameFull: Zwaan CM
      – PersonEntity:
          Name:
            NameFull: Grove CS
      – PersonEntity:
          Name:
            NameFull: Stone R
      – PersonEntity:
          Name:
            NameFull: Shami PJ
      – PersonEntity:
          Name:
            NameFull: Mantzaris I
      – PersonEntity:
          Name:
            NameFull: Greenwood M
      – PersonEntity:
          Name:
            NameFull: Shukla N
      – PersonEntity:
          Name:
            NameFull: Cuglievan B
      – PersonEntity:
          Name:
            NameFull: Kovacsovics T
      – PersonEntity:
          Name:
            NameFull: Gu Y
      – PersonEntity:
          Name:
            NameFull: Bagley RG
      – PersonEntity:
          Name:
            NameFull: Madigan K
      – PersonEntity:
          Name:
            NameFull: Chudnovsky Y
      – PersonEntity:
          Name:
            NameFull: Nguyen HV
      – PersonEntity:
          Name:
            NameFull: McNeer N
      – PersonEntity:
          Name:
            NameFull: Stein EM
    IsPartOfRelationships:
      – BibEntity:
          Dates:
            – D: 01
              M: 01
              Text: 2025 Jan
              Type: published
              Y: 2025
          Identifiers:
            – Type: issn-electronic
              Value: 1527-7755
          Numbering:
            – Type: volume
              Value: 43
            – Type: issue
              Value: 1
          Titles:
            – TitleFull: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
              Type: main
ResultId 1